GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mosaic Immunoengineering CPMV · USD

Information Technology · US listing · 🇺🇸 United States

Compare

0.06

-24.05%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Mosaic Immunoengineering

From its filings with the US Securities and Exchange Commission

SEC filings

Mosaic Immunoengineering is based in Huntington Beach, California and is incorporated in Delaware. Its shares trade on OTC under the ticker CPMV. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $687,846. At that date it held total assets of $19,882 and shareholders' equity of −$7.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Information Technology
Industry
Semiconductors & Semiconductor Equipment
Listed since
28 Oct 1993
Employees
4
Head office
9114 ADAMS AVE., HUNTINGTON BEACH, CA, 92646
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Steven KingPresident, Chief Executive Officer, Director, since 2020$250,000
  • Mr. Paul LytleChief Financial Officer, Executive Vice President, Corporate Secretary, Director, since 2020$116,846
  • Dr. Robert BaffiIndependent Director$86,000
  • Dr. Robert GarnickIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Mosaic ImmunoEngineering's CPMV platform technology is non-infectious to humans and animals.
  • MIE-101 product candidate targets multiple cancer types with in-situ vaccine approach.
  • Huntington Beach headquarters supports biotechnology development in California.

Weaknesses

  • Mosaic ImmunoEngineering has only 4 full-time employees.
  • The company is a development-stage biotechnology firm with no commercial products.
  • MIE-101 is still in development without regulatory approval.

Opportunities

  • California's biotechnology sector offers growth opportunities for Mosaic ImmunoEngineering.
  • The CPMV platform could expand to new cancer treatments and markets.
  • MIE-101's in-situ vaccine approach may attract research partnerships.

Threats

  • Mosaic ImmunoEngineering faces competition from other biotechnology companies.
  • Regulatory hurdles could delay MIE-101's approval process.
  • The development-stage status may deter potential investors.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.